Collect of Cord Blood From Subjects at Risk for Sickle Cell Disease, for the Purpose of Laboratory Research

Institut National de la Santé Et de la Recherche Médicale, France1 site in 1 country44 target enrollmentOctober 23, 2019

ConditionsSickle Cell Disease

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Sickle Cell Disease
Sponsor: Institut National de la Santé Et de la Recherche Médicale, France
Enrollment: 44
Locations: 1
Primary Endpoint: Number of samples with HbS/HbS genotype
Status: Completed
Last Updated: 5 months ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The study consists in collecting umbilical cord blood cells from newborns at risk of sickle cell disease, to perform laboratory experiments aiming to characterize the cells with HbS/HbS mutation, to develop methods to prepare, to gene-modify and to preserve these cells.

Detailed Description

Pregnant individuals carrying at least one HbS allele will be included in the study to collect the umbilical cord blood of the child at birth. Collected cells will be used anonymously for genetic and bioexperimental laboratory research, aiming to develop autologous gene therapy for sickle cell disease.

Registry

clinicaltrials.gov

Start Date

October 23, 2019

End Date

October 23, 2023

Last Updated

5 months ago

Study Type

Observational

Sex

Female

Investigators

Sponsor

Institut National de la Santé Et de la Recherche Médicale, France

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Pregnant women, giving birth at CHSF and consenting to the collect and study of placental blood after delivery
•Age 18 to 45 years
•Biological testing of the participant includes hemoglobin electrophoresis and shows at least one HbS allele